<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04235205</url>
  </required_header>
  <id_info>
    <org_study_id>YCU19002</org_study_id>
    <nct_id>NCT04235205</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Patients With Nonalcoholic Fatty Liver Disease: a Single Center, Double-blind, Randomized, Placebo-Controlled, Phase 2a Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yokohama City University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EA Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yokohama City University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the efficacy and safety of once-daily oral doses of 10 mg&#xD;
      elobixibat in combination with 9g cholestyramine powder (cholestyramine 4g) in patients with&#xD;
      nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo-controlled, randomized, double-blind, parallel group, comparative study,&#xD;
      when patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis&#xD;
      (NASH), are administered elobixibat at 10 mg and cholestyramine powder at 9g( cholestyramine&#xD;
      4g) once daily for 16 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 21, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change from baseline in serum LDL-C at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline to Week 16 in the liver fat fraction (%) as measured by MRI-PDFF</measure>
    <time_frame>Week 16</time_frame>
    <description>MRI-PDFF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline to Week 16 in hepatic fibrosis as measured by MRE</measure>
    <time_frame>Week 16</time_frame>
    <description>MRE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 16 in ALT level</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 16 in AST level</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 16 in γ-GTP level</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline to Week 16 in HDL-C level</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 16 in non HDL-C level</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 16 in LDL-C/HDL-C ratio</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 16 in TG level</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Nonalcoholic Fatty Liver</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Elobixibat and cholestyramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigational product per dosing (elobixibat 10mg and cholestyramine powder 9g) are orally administered once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elobixibat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigational product per dosing (elobixibat 10mg and cholestyramine powder placebo) are orally administered once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cholestyramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigational product per dosing (elobixibat placebo and cholestyramine powder 9g) are orally administered once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The investigational product per dosing (elobixibat placebo and cholestyramine powder placebo) are orally administered once daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)</intervention_name>
    <description>Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks</description>
    <arm_group_label>Elobixibat and cholestyramine</arm_group_label>
    <other_name>AJG533 10 mg + CTM27 9 g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elobixibat 10mg + cholestyramine powder placebo</intervention_name>
    <description>Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks</description>
    <arm_group_label>Elobixibat</arm_group_label>
    <other_name>AJG533 10 mg + CTM27 placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)</intervention_name>
    <description>Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks</description>
    <arm_group_label>cholestyramine</arm_group_label>
    <other_name>AJG533 placebo + CTM27 9g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elobixibat placebo + cholestyramine powder placebo</intervention_name>
    <description>Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>AJG533 placebo + CTM27 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who received adequate explanation about this study and provided written&#xD;
             informed consent&#xD;
&#xD;
          -  Patients who are ≥ 20 and &lt; 75 years of age at the time of informed consent&#xD;
&#xD;
          -  Patients who have a current biopsy-confirmed NASH within 8 months of screening or a&#xD;
             suspected diagnosis of NAFLD/NASH based on the criteria outlined below:&#xD;
&#xD;
               1. Biopsy-confirmed NASH is defined as histological NASH diagnosis with fibrosis&#xD;
                  stage F1 through F3 and a NAFLD activity score (NAS) of ≥4 with a score of ≥1 in&#xD;
                  each of the NAS components below as assessed by a pathologist using the NASH&#xD;
                  Clinical Research Network criteria:&#xD;
&#xD;
                  i. Steatosis (scored 0 to 3)&#xD;
&#xD;
                  ii. Ballooning degeneration (scored 0 to 2)&#xD;
&#xD;
                  iii. Lobular inflammation (scored 0 to 3)&#xD;
&#xD;
               2. The suspected diagnosis of NAFLD/NASH is based on the following criteria:&#xD;
&#xD;
                  i. Serum aspartate aminotransferase (AST) ≥20 U/L and alanine aminotransferase&#xD;
                  (ALT) ≥40 U/L in males or ≥28 U/L in females&#xD;
&#xD;
                  ii. Waist circumference ≥85 cm in males or ≥90 cm in females&#xD;
&#xD;
                  iii. Diagnosis of metabolic syndrome having 2 or more of the following 3 risk&#xD;
                  factors at Screening:&#xD;
&#xD;
                    1. Fasting plasma glucose ≥110 mg/dL or undergoing drug treatment for elevated&#xD;
                       glucose&#xD;
&#xD;
                    2. Systolic blood pressure ≥130 mmHg and/or diastolic blood pressure≥85mmHg or&#xD;
                       undergoing drug treatment for hypertension, or antihypertensive drug&#xD;
                       treatment in a patient with a history of hypertension&#xD;
&#xD;
                    3. Triglycerides (TGs) ≥150 mg/dL or undergoing drug treatment for elevated&#xD;
                       triglycerides,and/or high-density lipoprotein-cholesterol (HDL-C)&lt;40mg/dL or&#xD;
                       undergoing drug treatment for reduced HDL-C&#xD;
&#xD;
          -  Screening Magnetic Resonance Imaging (MRI) -Proton Density Fat Fraction (PDFF) with&#xD;
             ≥8% liver steatosis&#xD;
&#xD;
          -  Fasting serum low density lipoprotein-cholesterol (LDL-C) &gt;120 mg/dL or undergoing&#xD;
             antidyslipidemic drugs&#xD;
&#xD;
          -  Be willing to maintain a stable diet and physical activity throughout the course of&#xD;
             the study&#xD;
&#xD;
        Exclusion criteria：&#xD;
&#xD;
          -  Women who are pregnant, breastfeeding, possibly pregnant or do not agree to use birth&#xD;
             control during the study&#xD;
&#xD;
          -  Body mass index (BMI) &lt;23 kg/m²&#xD;
&#xD;
          -  Magnetic Resonance Elastography (MRE) value &gt;6.7 kPa&#xD;
&#xD;
          -  Any of the following laboratory abnormalities:&#xD;
&#xD;
               1. ALT &gt;5 × upper limit normal (ULN) or AST &gt;5 × ULN&#xD;
&#xD;
               2. Prothrombin time - international normalized ratio (PT-INR) ≥1.3 unless on&#xD;
                  anticoagulant therapy&#xD;
&#xD;
               3. Total bilirubin &gt; ULN, except with an established diagnosis of Gilbert's syndrome&#xD;
&#xD;
               4. Platelet count &lt; 80,000/μL&#xD;
&#xD;
               5. eGFR &lt;45 as calculated by the body surface area (BSA) adjustment (normalized&#xD;
                  eGFR)&#xD;
&#xD;
          -  Acute or chronic liver disease other than NAFLD/NASH including but not limited to the&#xD;
             following:&#xD;
&#xD;
               1. Hepatitis B (as defined by the presence of hepatitis B surface [HBs] antigen at&#xD;
                  Screening) or hepatitis C(as defined by the presence of hepatitis C virus [HCV]&#xD;
                  antibody [anti-HCV]) Patients with positive anti-HCV who test negative for HCV&#xD;
                  ribonucleic acid (HCV-RNA) at Screening will be allowed to participate in the&#xD;
                  study as long as there is evidence of viral negativity for a minimum of 12 months&#xD;
                  prior to Screening&#xD;
&#xD;
               2. Evidence of autoimmune hepatitis&#xD;
&#xD;
               3. History of primary biliary cholangitis, primary sclerosing cholangitis, Wilson's&#xD;
                  disease, alpha-1-anti-trypsin deficiency, hemochromatosis or iron overload,&#xD;
                  drug-induced or alcoholic liver disease, or known bile duct obstruction.&#xD;
&#xD;
               4. Suspected or proven hepatocellular carcinoma&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Medical history of liver cirrhosis&#xD;
&#xD;
          -  Clinical evidence of portal hypertension to include any history of ascites, hepatic&#xD;
             encephalopathy, or presence of esophageal varices&#xD;
&#xD;
          -  Use of drugs historically associated with NAFLD (amiodarone, methotrexate, systemic&#xD;
             glucocorticoids, tetracyclines,tamoxifen, estrogens at doses greater than those used&#xD;
             for hormone replacement, anabolic steroids, or valproic acid) or other known&#xD;
             hepatotoxins for ≥2 weeks in the year prior to Screening&#xD;
&#xD;
          -  Use of the following medications:&#xD;
&#xD;
               1. Glucagon-like peptide-1 (GLP-1) agonists unless on a stable dose 3 months prior&#xD;
                  to Screening or liver biopsy&#xD;
&#xD;
               2. Ursodeoxycholic acid or thiazolidinediones within 3 months prior to Screening&#xD;
&#xD;
               3. Antidyslipidemic drugs have been stable for ≥3 months prior to Screening&#xD;
&#xD;
               4. Oral antidiabetic drugs have been stable for ≥3 months prior to Screening&#xD;
&#xD;
               5. Agents (including herbal over-the-counter weight loss preparations) or&#xD;
                  medications known to significantly impact body weight within 3 months prior to&#xD;
                  Screening&#xD;
&#xD;
          -  History of significant alcohol consumption, defined as an average of≥20g/day in female&#xD;
             patients and ≥30 g/day in male patients, for a period of &gt;3 consecutive months within&#xD;
             1 year prior to Screening, hazardous alcohol use (Alcohol Use Disorders Identification&#xD;
             Test score ≥8), or an inability to reliably quantify alcohol consumption but&#xD;
             determined as alcohol polydipsia based upon judgment of the Investigator or&#xD;
             subinvestigator&#xD;
&#xD;
          -  Weight change ≥10% within the 6 months prior to Screening or ≥5% within the 3 months&#xD;
             prior to Screening&#xD;
&#xD;
          -  Surgery planned during the study period or after bariatric surgery (e.g., gastroplasty&#xD;
             and roux-en-Y gastric bypass)&#xD;
&#xD;
          -  Type 1 diabetes by medical history&#xD;
&#xD;
          -  Uncontrolled Type 2 diabetes defined as hemoglobin A1c (HbA1c) &gt;9.5% at&#xD;
             Screening(patients with HbA1c &gt;9.5% may be rescreened) or requiring insulin dose&#xD;
             adjustment &gt;10% within 2 months prior to Screening&#xD;
&#xD;
          -  Clinical hyperthyroidism or hypothyroidism or Screening hormone results pointing to&#xD;
             thyroid dysfunction. Patients receiving dose-stable thyroid replacement therapy for ≥3&#xD;
             months prior to Screening will be allowed to participate in this study as long as&#xD;
             thyroid tests show that the patient is euthyroid and stable&#xD;
&#xD;
          -  History of any condition causing malabsorption such as chronic pancreatitis, extensive&#xD;
             bowel/small intestine surgery, celiac disease, or bile flow obstruction&#xD;
&#xD;
          -  History of any condition associated with acute or chronic diarrhea such as&#xD;
             inflammatory bowel disease (IBD),functional diarrhea, irritable bowel syndrome (IBS)&#xD;
             with predominant diarrhea, IBS with mixed bowel habits, or unclassified IBS&#xD;
&#xD;
          -  Uncontrolled hypertension (either treated or untreated) defined as systolic blood&#xD;
             pressure &gt;160 mmHg or a diastolic blood pressure &gt;100 mmHg at Screening&#xD;
&#xD;
          -  History of New York Heart Association (NYHA) Class III or IV heart failure, or known&#xD;
             left ventricular ejection fraction &lt;30%&#xD;
&#xD;
          -  History of myocardial infarction, unstable angina, percutaneous coronary intervention,&#xD;
             coronary artery bypass graft, or stroke or major surgery within 6 months prior to&#xD;
             Screening&#xD;
&#xD;
          -  Active substance abuse, within 1 year prior to Screening&#xD;
&#xD;
          -  Participation in an investigational new drug trial in the 30 days prior to Screening&#xD;
             or within 5 half-lives of an investigational agent, whichever is longer&#xD;
&#xD;
          -  Complication with malignancy Patients with a history of malignancies that have been&#xD;
             treated with curative intent or completed chemotherapy may be eligible. Patients under&#xD;
             evaluation for malignancy are not eligible&#xD;
&#xD;
          -  Known intolerance to MRI or conditions contraindicated for MRI procedures&#xD;
&#xD;
          -  Any other condition which is considered to be inappropriate for the study by the&#xD;
             Investigator or subinvestigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takaomi Kessoku, MD.,PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yokohama City University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yokohama City University</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg PG, Mattsson JP, Camilleri M. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018 Aug;3(8):537-547. doi: 10.1016/S2468-1253(18)30123-7. Epub 2018 May 25.</citation>
    <PMID>29805116</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yokohama City University</investigator_affiliation>
    <investigator_full_name>Takaomi Kessoku</investigator_full_name>
    <investigator_title>Department of palliative care center</investigator_title>
  </responsible_party>
  <keyword>Elobixibat</keyword>
  <keyword>Cholestyramine</keyword>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>Nonalcoholic steatohepatitis</keyword>
  <keyword>phase 2 trial</keyword>
  <keyword>Combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestyramine Resin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

